Chronic mucocutaneous candidiasis
ICD-10 B38.1 is a billable code used to indicate a diagnosis of chronic mucocutaneous candidiasis.
Chronic mucocutaneous candidiasis (CMC) is a rare, persistent fungal infection characterized by the overgrowth of Candida species, primarily Candida albicans, affecting the skin, nails, and mucous membranes. This condition is often associated with underlying immunological defects, particularly in patients with T-cell dysfunction, leading to recurrent and severe infections. CMC manifests as white patches in the oral cavity (oral thrush), chronic dermatitis, and nail infections, which can significantly impact the quality of life. Patients may experience discomfort, pain, and secondary bacterial infections due to skin breakdown. Diagnosis is typically made through clinical evaluation and laboratory tests, including culture and sensitivity testing of the Candida species. Treatment involves systemic antifungal therapy, such as fluconazole or itraconazole, and may require long-term management to prevent recurrences. In immunocompromised patients, such as those with HIV/AIDS or undergoing immunosuppressive therapy, the risk of CMC is heightened, necessitating vigilant monitoring and aggressive treatment strategies.
Detailed history of recurrent infections, immunological assessments, and treatment responses.
Patients with recurrent oral thrush, skin infections, or nail candidiasis.
Documentation of any underlying immunosuppressive conditions is crucial for accurate coding.
Clinical notes detailing skin manifestations, treatment plans, and follow-up assessments.
Patients presenting with chronic dermatitis or nail infections attributed to Candida.
Accurate description of skin lesions and response to antifungal treatments is necessary.
Used when laboratory confirmation of Candida infection is needed.
Document the reason for the culture and any previous treatment history.
Infectious disease specialists may require more detailed lab results.
Common symptoms include persistent oral thrush, chronic skin rashes, and nail infections. Patients may also experience discomfort and pain in affected areas.
Treatment typically involves systemic antifungal medications such as fluconazole or itraconazole, along with topical treatments for localized infections.
Individuals with immunocompromised conditions, such as those with HIV/AIDS, diabetes, or undergoing immunosuppressive therapy, are at higher risk.
